Name | 3-(2,4-dimethoxybenzylidene)anabaseine |
Synonyms | DMBX-anabaseine GTS-21 (DMXB-A) 3-(2,4-dimethoxybenzylidene)anabaseine 3-(2,4)-DiMethoxybenzylidineanabaseine 3-(2,4-Dimethoxy-benzyl)-3,4,5,6-tetrahydro-[2,3']bipyridinyl 3-(2,4-DiMethoxy-benzyl)-3,4,5,6-tetrahydro-[2,3']bipyridinyl Dihydrochloride (3E)-3-[(2,4-Dimethoxyphenyl)methylene]-3,4,5,6-tetrahydro-2,3'-Bipyridine dihydrochloride 3-[(3E)-3-[(2,4-dimethoxyphenyl)methylidene]-5,6-dihydro-4H-pyridin-2-yl]pyridine dihydrochloride |
CAS | 156223-05-1 |
InChIKey | RPYWXZCFYPVCNQ-RVDMUPIBSA-N |
Molecular Formula | C19H22Cl2N2O2 |
Melting Point | 216-217℃ (decomposition) |
Solubility | H2O: >5mg/mL |
Appearance | powder |
Color | faint yellow to dark yellow |
Storage Condition | 2-8°C |
In vitro study | GTS-21 bound to human α4β2 nAChR (K i =20 nM) 100-fold more potently than to humanα7-nAChR, and is 18- and 2-fold less potent than (-)-nicotine at human α4β2 and a7 nAChR, respectively. |
In vivo study | GTS 21 (4 mg/kg; i.p.; 1, 3, 7, 14 and 21 days) reduces radiation induced histological signs of pulmonary injury. Animal Model: C57BL6 mice were irradiated with 12 Gy to induce a mouse model of Radiation induced lung injury (RILI) Dosage: 4 mg/kg Administration: I.p.; 1, 3, 7, 14 and 21 days Result: Reduces lung inflammatory infiltrate and fibrosis in radiation treated mice. |
WGK Germany | 3 |
RTECS | DW1764860 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.623 ml | 13.113 ml | 26.226 ml |
5 mM | 0.525 ml | 2.623 ml | 5.245 ml |
10 mM | 0.262 ml | 1.311 ml | 2.623 ml |
5 mM | 0.052 ml | 0.262 ml | 0.525 ml |